Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

IASLC: Adjunctive use of 3-D imaging system increases utility of CT lung cancer screening

04.07.2011
IASLC presentation addresses key issue from landmark NLST lung cancer study -- how to manage high rate of false positive results; lays out protocol for adjunctive use of noninvasive diagnostic test to clarify false positives from CT screening

Amsterdam, the Netherlands and Phoenix, AZ, USA – July 4, 2011 – VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today announced that it will present data showing how adjunctive use of its LuCED™ test can improve the utility of low dose x-ray computed tomography (CT) screening for the early detection of lung cancer in high risk individuals.

LuCED uses VisionGate's revolutionary automated 3D cell imaging platform, the Cell-CT™, which generates high-resolution 3D biosignatures from intact cells using a sputum sample. The data will be presented at the International Association for the Study of Lung Cancer's 14th World Conference on Lung Cancer on July 7, 2011 from 9:30am-12:30pm CEST.

The proposed first use of LuCED as an adjunct to CT screening reflects the results of the National Cancer Institute's (NCI) landmark National Lung Screening Trial (NLST) of more than 53,000 current and former heavy smokers, which showed that low-dose helical CT screening reduced lung cancer deaths by 20% compared to standard chest x-rays. These dramatic results were first presented last November and were expanded this week in the June 29, 2011 online edition of the New England Journal of Medicine.

The NLST findings are generating widespread interest in the broad use of CT screening as a way to reduce lung cancer deaths in high-risk populations. However, the utility of the approach is hampered by the high rate of false positive results seen in the study—according to the NCI, more than 96% of the positive results from low-dose CT screening over three rounds of testing turned out to be false positive findings, representing almost a quarter (23.3%) of the overall test results. These false positive test results require follow-up care that results in unnecessary invasive procedures for many patients and significantly higher costs for the healthcare system as a whole, potentially jeopardizing the feasibility of implementing mass screening programs for the millions of individuals at high risk for lung cancer.

In its presentation, VisionGate shows how LuCED harnesses the power of 3D imaging to accurately detect cancer cells when present in sputum samples from individuals at high risk of lung cancer. The presentation outlines patient management protocols for the non-invasive and efficient use of LuCED as an adjunct to CT screening to confirm which cases are true positives and to lower significantly the number of cases which are false positives.

Dr. Claudia Henschke, a lung cancer researcher at the Biodesign Institute at Arizona State University who is also a practicing physician at Mount Sinai Medical Center in New York City, serves as a leader of the International Early Lung Cancer Action Program. She is co-author of a pioneering study of the benefits of CT scans for lung cancer that was published in the New England Journal of Medicine in 2006.

Dr. Henschke noted, "Today, almost all patients diagnosed with lung cancer in the U.S. die. The NLST study results released last November confirmed our initial findings showing that CT scans can find lung cancers in their earliest stage, when up to 92% can be cured. VisionGate's LuCED technology has demonstrated promise as an approach that may increase the feasibility of implementing widespread screening of high risk individuals, initially being used as an adjunct to improve the accuracy of CT scan results, with the potential to be used as a primary screening tool if additional trials are successful. We look forward to the opportunity to contribute to assessments of its potential utility in helping to reduce the death rate from this lethal cancer that affects so many people around the globe."

LuCED uses the company's breakthrough automated Cell-CT platform to produce detailed 3D images of the cells contained in sputum samples, which the system analyzes to identify key features associated with potential malignancy. The analysis yields a score that indicates whether or not cancer cells are present in the sample. The Cell-CT system produces strikingly clear and comprehensive 3D images of the cells, enabling extremely accurate classifications. VisionGate researchers estimate that LuCED will be able to achieve specificity of 99% and sensitivity of 75% in actual use.

"The dramatic results of the NLST study provide us with a valuable initial indication for our LuCED test," commented Scarlett Spring, president of VisionGate. "By combining the high accuracy and cost effectiveness of our non-invasive LuCED diagnostic with the proven ability of CT screening to reduce lung cancer deaths, we hope to make mass screening feasible and affordable. We believe that we have developed an efficient clinical and regulatory strategy for our proposed use of LuCED to manage the false positive results from CT screening, and we look forward to advancing this program in the coming months."

Prior to the development of LuCED, a number of studies had confirmed that analyzing cells in sputum could potentially be useful in the early detection of lung cancer, showing that 85% of sputum samples from individuals with lung cancer (the samples were taken over three days and pooled) actually contained cancer cells. However, the typically poor sensitivity of raw sputum analysis and the labor intensive nature of the process made it impracticable for widespread use in lung cancer screening. The Cell-CT platform's 3D technology, along with its advanced automated 3D image analysis algorithms, for the first time make a cell-based sputum analysis approach both logistically feasible and cost effective.

VisionGate's poster (P4.007), "The LuCED Test for Detection of Early Lung Cancer: A Criterion to Complete the Test with High Sensitivity," will be presented by Michael Meyer on July 7, 2011 from 9:30am-12:30pm CEST.

The IASLC's 14th World Conference on Lung Cancer is being held in Amsterdam, the Netherlands from July 3-July 7, 2011. For more information, visit www.2011worldlungcancer.org/

About the International Association for the Study of Lung Cancer (IASLC)

Founded in 1972, the International Association for the Study of Lung Cancer (IASLC) is an international organization of nearly 3,000 lung cancer specialists spanning 80 countries. IASLC members work towards developing and promoting the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies. IASLC's mission is to enhance the understanding and education of lung cancer to scientists, members of the medical community and the public. In addition to the biannual meeting, the IASLC publishes the Journal of Thoracic Oncology, a prized resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

About VisionGate

VisionGate, Inc. is developing a revolutionary non-invasive test for the early detection of lung cancer, using its automated 3D cell imaging platform, the Cell-CT™, which generates high-resolution 3D biosignatures from intact cells using a sputum sample. The company's LuCED™ test is initially being developed for adjunctive use with low dose x-ray computed tomography (CT) screening for the early detection of lung cancer in high risk individuals. Adjunctive use of LuCED to better manage the high rate of false positive results in CT screening could increase the utility and cost effectiveness of the approach, which has been shown to decrease lung cancer deaths in former and current smokers. For more information, visit www.visiongate3D.com.

Barbara Lindheim | EurekAlert!
Further information:
http://www.biocompartners.com

More articles from Medical Engineering:

nachricht 3-D visualization of the pancreas -- new tool in diabetes research
15.03.2017 | Umea University

nachricht New PET radiotracer identifies inflammation in life-threatening atherosclerosis
02.03.2017 | Society of Nuclear Medicine

All articles from Medical Engineering >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Researchers use light to remotely control curvature of plastics

23.03.2017 | Power and Electrical Engineering

Sea ice extent sinks to record lows at both poles

23.03.2017 | Earth Sciences

Inactivate vaccines faster and more effectively using electron beams

23.03.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>